
Materials Today Bio, Journal Year: 2024, Volume and Issue: 29, P. 101346 - 101346
Published: Nov. 16, 2024
Language: Английский
Materials Today Bio, Journal Year: 2024, Volume and Issue: 29, P. 101346 - 101346
Published: Nov. 16, 2024
Language: Английский
Advanced Science, Journal Year: 2024, Volume and Issue: unknown
Published: July 7, 2024
Immune checkpoint blockade (ICB) immunotherapy remains hampered by insufficient immunogenicity and a high-lactate immunosuppressive tumor microenvironment (TME). Herein, nanobody-engineered NIR-II nanoadjuvant with targeting metabolic reprogramming capability is constructed for potentiating photothermal-ferroptosis immunotherapy. Specifically, the (2DG@FS-Nb) prepared metallic iron ion-mediated coordination self-assembly of D-A-D type molecules loading glycolysis inhibitor, 2-deoxy-D-glucose (2DG), followed modification aPD-L1 nanobody (Nb), which can effectively target TME trigger in situ immune blockade. The nanoadjuvants responsively release therapeutic components acidic TME, enabling precise location fluorescence/photoacoustic imaging while initiating therapy. remarkable photothermal efficiency elevated glutathione (GSH) depletion further sensitize ferroptosis to induce severe lipid peroxidation, provoking robust immunogenic cell death (ICD) anti-tumor response. Importantly, released 2DG markedly inhibits lactate generation through obstruction. Decreased efflux remodels suppressing M2 macrophage proliferation downregulating regulatory T levels. This work provides new paradigm integration phototheranostics metabolism regulation into single nanoplatform amplified combined ICB
Language: Английский
Citations
9Chemical Engineering Journal, Journal Year: 2025, Volume and Issue: 505, P. 159676 - 159676
Published: Jan. 17, 2025
Language: Английский
Citations
1Small, Journal Year: 2025, Volume and Issue: unknown
Published: March 6, 2025
At present, tumor immune escape is a major problem in the treatment of tumors. The complex network microenvironments significantly impairs efficacy immunotherapy. This paper reports preparation and immunoantitumor activity novel multifunctional defect tungsten trioxide@ferrocene-folic acid composite (WO3-x@Fe-FA) with high Fenton reaction rate. Ferrocene modified on surface defective trioxide by covalent coupling method for first time, rate increased 10 times. WO3-x@Fe-FA induces immunogenic cell death (ICD) through powerful synergistic anti-tumor effect PTT/CDT decomposes H2O2 to produce oxygen reaction, thus down-regulating expression checkpoint PD-L1 induced hypoxia. In vitro vivo experiments proved that reverses immunosuppressive microenvironment, transforms "cold tumor" into "hot tumor", activates system. show has excellent activity, it expected be candidate drug therapy.
Language: Английский
Citations
0Advanced Functional Materials, Journal Year: 2025, Volume and Issue: unknown
Published: March 4, 2025
Abstract Cancer immunotherapy, which leverages the body's immune system to combat cancer, offers promise of lower toxicity and higher therapeutic efficacy compared conventional treatments. However, current immunotherapeutic approaches face significant challenges including variable patient response, immune‐related adverse events, high costs, underscoring urgent need for innovative strategies. Metal‐based nanomaterials have emerged as a promising avenue in cancer immunotherapy due their unique physicochemical properties immune‐regulating capabilities. Despite potential, concerns about toxicity, incomplete understanding modulation mechanisms, early‐stage design strategies hinder clinical translation. This review summarizes recent advancements metal‐based elucidates mechanisms by they enhance antitumor immunity responses, explores potential synergistic effects combining multiple metals. We also discuss key future perspectives application, aiming provide theoretical foundation development immunotherapies promote broader application treatment.
Language: Английский
Citations
0Journal of Nanobiotechnology, Journal Year: 2025, Volume and Issue: 23(1)
Published: March 19, 2025
Inducing ferroptotic cell death has been recognized as a promising approach in cancer therapy. However, ferroptosis can provoke tumor infiltration by myeloid-derived suppressor cells (MDSCs) through HMGB1 secretion, causing suppressive immune response. On the other hand, also occurs due to its non-selective properties, which compromise anti-tumor immunity. To address these challenges, two-pronged is proposed, encompassing selectively triggered and blockade, aimed at eliciting systemic immunity alleviating immunosuppression. Herein, GSH-specific driven nanoplatform composed of uniform FeOOH nanospindles coated with tetrasulfide bond-bridged mesoporous organosilica (DMOS) shell, loaded inhibitor, glycyrrhizic acid (GA). This endowed high glutathione (GSH) depletion efficiency exhibits highly efficient Fe2+ ROS generation capacity, promotes accumulation LPO subsequently induces ferroptosis. Concurrently, inhibition release counteracts immunosuppressive effects within microenvironment. innovative effectively suppresses growth 4T1 tumors notably enhancing therapeutic outcomes checkpoint blockade across experimental data. The collective findings indicate potential reliable strategy for boosting ferroptosis-mediated favorable safety profiles.
Language: Английский
Citations
0Biomedicines, Journal Year: 2025, Volume and Issue: 13(4), P. 950 - 950
Published: April 12, 2025
Immunogenic cell death (ICD) is a promising cancer therapy where dying tumor cells release damage-associated molecular patterns (DAMPs) to activate immune responses. Recent research highlights the critical role of metabolic reprogramming in cells, including Warburg effect, oxidative stress, and lipid metabolism, modulating ICD shaping microenvironment. These changes enhance activation, making tumors more susceptible surveillance. This review explores mechanisms linking mitochondrial endoplasmic reticulum (ER) ferroptosis. It also discusses innovative therapeutic strategies, such as personalized combination therapies, inhibitors, targeted delivery systems, improve efficacy. The future immunotherapy lies integrating activation overcome evasion, with multi-omics approaches microbiome modulation offering new avenues for enhanced treatment outcomes.
Language: Английский
Citations
0Nano Biomedicine and Engineering, Journal Year: 2024, Volume and Issue: unknown
Published: Oct. 1, 2024
Language: Английский
Citations
3Chemical Engineering Journal, Journal Year: 2024, Volume and Issue: 500, P. 157141 - 157141
Published: Oct. 28, 2024
Language: Английский
Citations
0Materials Today Bio, Journal Year: 2024, Volume and Issue: 29, P. 101346 - 101346
Published: Nov. 16, 2024
Language: Английский
Citations
0